Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE versus NAPROSYN.
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Diphenhydramine is an antihistamine that antagonizes histamine H1 receptors.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
1-2 tablets (200 mg ibuprofen/25 mg diphenhydramine HCl each) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Ibuprofen: 2-4 hours (immediate-release). Diphenhydramine: 8-12 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Ibuprofen: Renal (90% as glucuronide conjugates, <10% unchanged). Diphenhydramine: Renal (primarily as metabolites, <10% unchanged). Both undergo hepatic metabolism with renal excretion of metabolites.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID
NSAID